Topic: age-related macular degeneration
Biogen is putting down $100 million upfront for copycats to Roche's Lucentis, Regeneron's Eylea and new rights for anti-TNF drugs in China.
Novartis' Beovu will be going up against entrenched rivals with a couple blemishes in its label, analysts wrote.
Novartis has its next big drug approval. The FDA on Tuesday approved wet AMD drug Beovu, which will go up against Regeneron and Roche meds.
Regeneron and Roche are already duking it out in wet age-related macular degeneration with Eylea and Lucentis, respectively, and they may have more company later this year.
Regeneron CEO Len Schleifer netted $26.5 million in pay in 2018, keeping him among the top three highest-earning CEOs in the industry.
Novartis is “actively evaluating” digital therapeutics for potential deals, according to the exec heading up its post-Alcon eye business.
To focus as what CEO Vas Narasimhan calls “a medicines company,” Novartis made a series of M&A decisions in 2018.
Roche grew sales by 7% in 2018, even as biosimilar rivals unleashed damage in Europe. But 2019 will be the moment of truth for the Swiss drugmaker. U.S. copycats to its trio of cancer megablockbusters—Herceptin, Rituxan and Avastin—are expected to arrive.
Bayer’s Xarelto and Eylea are still the top performers within the company’s pharma business. But both drugs are looking at a bumpy road ahead.